Document:

Prepared by R.R. Donnelley Financial -- EX-10.16(b)

 Exhibit 10.16(b) 

 

CONFIDENTIAL 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

  

			
	 

	 	 PURCHASE

ORDER
  

Purchase Order No: 2054            

 
 Date:
04/23/2014            

  

			
	 VENDOR:
 Medpace, Inc.

5375 Medpace Way
 Cincinnati, OH45227

United States
 T: F:

Email:
	  	 SHIP TO:
 Coherus Bioscience, Inc.

ATTN: Barbara Finck
 201 Redwood Shores Parkway, Suite 200

Redwood City, CA 94065
 T: 650-649-3530

E: bfinck@coherus.com

  

									
	 REQUISITIONER
	  	 SHIP BY
	  	 SHIPPED VIA
	  	 F.O.B. POINT
	  	 TERMS

	 Barbara Finck
	  		  	Best Method	  	Destination	  	Net 30

  

															
	 QTY
	  	UNIT	 	  	 DESCRIPTION
	  	UNIT
PRICE	 	  	TOTAL	 
	[***]	  	 	Each	  	  	Per Amendment #1 to Task Order #13. Pass Through Costs.	  	 	[***]	  	  	 	[***]	  
		  				  		  				  	  
	  
	 
		  				  		  	 	TOTAL	  	  	 	[***]	  
		  				  		  				  	  
	  
	 

 Please reference PO number on all invoices, shipping documents and related correspondence. Thank you! 

BILL TO:    COHERUS BIOSCIENCES, INC. 

  ATTN: Accounts Payable 

  201 Redwood Shores Parkway, #200 

  Redwood City, CA 94056 – USA 

  T: 650-649-3530 F: 866-491-7350 
  

	
	/s/ J. M. Clark                 4/23/14
	Authorized by                 Date

 AMENDMENT #1 TO TASK ORDER #13 

COHERUS Project Number. CHS-0214-02 

MEDPACE Project Number: ETA302 

This Amendment #1 (“Amendment #1”) to Task Order #13 effective as of October 18, 2013 (“Task Order”), is by
and between Coherus Biosciences, Inc., a Delaware corporation with its principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 (“Sponsor”), and Medpace, Inc., with its principal place of
business at 5375 Medpace Way, Cincinnati, Ohio 45227 (“Medpace”). This Amendment #1 shall be effective April 23, 2014. 

WITNESSETH: 

WHEREAS, the Parties have entered into Task Order pursuant and subject to the terms of the Master Service Agreement dated
January 23, 2012, (the “Master Service Agreement”); and 
 WHEREAS, the Parties desire to amend Task Order in
connection with A Phase 3, Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid Arthritis
and Inadequate Response to Treatment with Methotrexate (METEOR) to add Medpace Reference Laboratories (“MRL”) Services and Fees, which includes [***] vendor services. 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows to the revised Scope of
Work. 
  

	 	1.	Appendix A: Scope of Work, attached to Task Order #13 is hereby amended to include MRL and [***] start-up services included in Appendix F attached to this Amendment #1. 

 

	 	2.	Appendix B: Services, Budget, attached to Task Order #13 is hereby amended to include MRL and [***] fees included in Appendix F attached to this Amendment #1. 

 

	 	3.	As a result of the increase in the Budget, Appendix C: Payment Schedule, attached to Task Order #13 is hereby amended to increase the [***] upfront payment of Pass-through Costs by [***], which increase is due upon
execution of this Amendment #1. 

  

	 	4.	Sponsor Obligations transferred to Medpace by Sponsor (consistent with the regulations set forth in 21 C.F.R. Section 312, Subpart D) are identified in Appendix E attached to this Amendment #1. 

The total amount payable by Sponsor to Medpace under this Amendment #1 for Medpace Direct Fees, Pass-through Expenses, and Pre-funded Expenses shall not
exceed the amount of 

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

 
[***] without prior written consent of both parties. The total value of the Task Order and all subsequent amendments is now [***]. 

 

									
	 	  	Direct Fees	  	Pass Through
Costs	  	Pre-funded
Expenses	  	TOTAL
	 Task Order #13
	  	[***]	  	[***]	  	[***]	  	[***]
	 Amendment #1
	  	[***]	  	[***]	  	[***]	  	[***]
	 TOTAL
	  	[***]	  	[***]	  	[***]	  	[***]

 All other provisions of the Agreement and Task Order shall remain unchanged and in effect. 

IN WITNESS WHEREOF, the Parties have hereunto signed this Amendment #1 to Task Order in their official capacities which shall be effective on the day
and year listed above. 
  

			
	MEDPACE, INC.
		
	Signature:	 	/s/ John Wynne
		
	By:	 	 John Wynne

		 	 (Print Name)
  

	Title:	 	Vice President
		 	Commercial Operations

  

			
	COHERUS BIOSCIENCES, INC.
		
	Signature:	 	/s/ Dennis M. Lanfear
		
	By:	 	 Dennis M. Lanfear

		 	 (Print Name)
  

	Title:	 	President & CEO 4/23/14

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

 APPENDIX E: TRANSFER OF OBLIGATIONS 

CONFIDENTIAL 
 Directions: Complete the form below
for Sponsor obligations that have been transferred in accordance with 21 CFR Part 312, Subpart D (Responsibilities of Sponsors). Forward the completed form to Sponsor’s Regulatory Affairs Department for submission to the
applicable regulatory agencies. 
  

							
	Drug:	  	CHS-0214 Versus Enbrel®	  	Study ID:	  	CHS-0214-02
				
	Study Title:	  	A Phase 3, Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel® in Subjects With Rheumatoid
Arthritis and Inadequate Response to Treatment with Methotrexate (METEOR)	  		  	
				
	CRO Name:	  	Medpace	  		  	
				
	CRO Address:	  	5375 Medpace Way, Cincinnati, Ohio 45227	  		  	

 OBLIGATIONS TRANSFERRED TO MEDPACE:
x THE APPROPRIATE BOX(ES). 

 ̈ All obligations in 21 CFR 312, Subpart D (Responsibilities of Sponsors) have been transferred to
Medpace. 
 x The following obligations have been transferred to Medpace: 

 

 Sec. 312.32: IND Safety Reports 

 

	 ̈	Promptly review safety information. 

  

	x	Notify all participating investigators in a written IND safety report of any AE associated with the drug that is both serious and unexpected. 

 

	 ̈	Notify the FDA in a written IND safety report of any AE associated with the drug that is both serious and unexpected. 

Sec. 312.53: Selecting investigators and monitors 
  

	x	(a) Select qualified investigators 

  

	x	(b) Control investigational drug shipment 

  

	x	(c) Obtain information from investigators 

  

	 	x	(1) Signed Form FDA-1572 

  

	 	x	(2) CV or other qualification statement 

  

	 	x	(3) Clinical protocol outline 

  

	 	x	(4) Financial disclosure information 

  

	x	(d) Select qualified monitors 

 Sec. 312.54: Emergency research 

 

	 ̈	(a) Monitor the progress of all studies involving an exception from informed consent. 

  

	x	(b) Monitor such studies to identify when an

 Sec. 312.57: Record keeping and record retention 

 

	x	(a) Maintain adequate records showing investigational drug receipt, shipment, or other disposition. 

  

	x	(b) Maintain complete and accurate records showing any financial interests of the investigator subject to 21 CFR 54. 

  

	x	(c) Retain the records and reports required by the regulations for 2 years after the marketing application is approved, or if not approved, until 2 years after investigational drug shipment is
discontinued and FDA has been notified. 

  

	 ̈	(d) Retain reserve samples of any test article and reference standard identified and used in bioequivalence or bioavailability studies. 

Sec. 312.58: Inspection of Sponsor’s records and reports 
  

	x	(a) Permit FDA personnel to have access to and copy and verify any records and reports related to the clinical

 

	 	
IRB determines that it can’t approve the research. 

 Sec. 312.55: Informing
investigators 
  

	x	(a) Provide sites with the current Inv. Brochure. 

  

	x	(b) Inform investigators of new observations on the drug, particularly with respect to AEs and safe use. 

Sec. 312.56: Review of ongoing investigations 
  

	 ̈	(a) Monitor the progress of all IND studies. 

  

	x	(b) Secure compliance from noncompliant investigators or discontinue drug shipments and end the investigator’s participation in the study. 

 

	x	(c) Review and evaluate the safety and efficacy results as it is obtained from the investigator. 

  

	x	(d) Discontinue use of the investigational drug if it is determined to present an unreasonable and significant risk to subjects, notify all IRBs and investigators, and assure the return or alternate disposition of
the drug from the investigators. 

	 	
investigation. 

  

	x	(b) Permit DEA personnel to have access to and copy records related to the shipment, delivery, receipt and disposition of any investigational controlled substance. Assure adequate storage precautions are taken for
investigational new drug substances listed in any schedule of the Controlled Substances Act. 

 Sec. 312.59: Disposition of unused
supply of investigational drug 
  

	x	Assure the return (or alternate disposition) of all unused supplies of the investigational drug from each discontinued/terminated investigator; maintain written records of any disposition of the investigational drug.

 Other 
  

	 ̈	Please describe any other applicable transfers below: 

 

 APPENDIX F: MRL AND [***] Services and Budget 

Sponsor: Coherus Biosciences
                                         
   22-Apr-14 
 Protocol: CHS-0214-02 Start-up 
  

					
	 [***]
	  		  	[***]
		  	[***]	  	[***]
		  	[***]	  	[***]
		  		  	  

	 Total Medpace Reference Laboratories Fees
	  		  	[***]

 Medpace Laboratory 
  

											
	 Sponsor: Coherus Biosciences

Protocol: CHS-0214-02 Start-up
                    [***]
	  		  	

 Number of Analyses Per Visit 

 

													
	 	  	 	  	Unit Cost	  	Screening
W-4	  	Total
Number
of Units	  	Cost	  	Subtotal
	 Laboratory Tests
	  		  		  		  		  	[***]
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
					
	 Laboratory Support Services
	  		  		  		  	[***]
							
	[***]	  		  		  		  		  		  	
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	
		  	[***]	  	[***]	  		  		  		  	
		  	[***]	  	[***]	  		  		  		  	
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	
		  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		  	[***]	  	[***]	  		  		  		  	
		  	[***]	  	[***]	  		  	[***]	  	[***]	  	

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

													
		 	[***]	  	[***]	  		  	[***]	  	[***]	  	
	[***]	 		  		  		  		  		  	
		 	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	
		 	[***]	  	[***]	  		  	[***]	  	[***]	  	
		 	[***]	  	[***]	  		  	[***]	  	[***]	  	
		 	[***]	  	[***]	  		  	[***]	  	[***]	  	
		 	[***]	  	[***]	  		  	[***]	  	[***]	  	
		 		  		  		  		  		  	  

	 Total Medpace Reference Laboratory Fees
	  		  	[***]
		 		  		  		  		  		  	  

 Medpace Reference Laboratories Pass Through Estimate 

Sponsor: Coherus Biosciences 
 Protocol: CHS-0214-02
Start-up 
  

											
	 	  	 	  	Total Cost	 	  	Subtotal	 
	 Pass Through Estimates
	  		  				  	 	[***]	  
	 [***]
	  		  				  			
		  	[***]	  	 	[***]	  	  			
		  	[***]	  	 	[***]	  	  			
		  		  				  	  
	  
	 
	 Total Estimated Medpace Reference Laboratory Pass-Through Fees
	  		  				  	 	[***]	  
		  		  				  	  
	  
	 

 Transportation Costs 
  

																																																	
	 Country
	  	Sites	 	  	Number
Screened	 	  	Number
Ambient/Refrigerate
Shipments	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	 	 
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  				  				  				  				  				  				  				  				  			
	 Total
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  	  				  	 	[***]	  	  				  	 	[***]	  	  				  	 	[***]	  	  			
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  				  				  				  				  				  				  				  				  	  
	  
	 
		  				  				  				  				  	 	[***]	  	  				  	 	[***]	  	  				  	 	[***]	  	  				  	 	[***]	  	  	 	[***]	  
		  				  				  				  				  				  				  				  				  				  				  				  	  
	  
	 

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

 CONFIDENTIAL 
  

					
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  

  

																					
	 Date, Version: [***]
 Prepared by [***]:
[***]
 Prepared for [***]: [***]
 Client & Protocol: Medpace
– CHS-0214-02
 Phase: III
[***]: [***]
[***]:  [***]
[***]:  [***]
[***]:  [***]
[***]:  [***]
	  	Unit Price
[***]	  	[***]	  	[***]	 	  	[***]	 	  	[***]	 	  	Total [***]	 
	 [***]: [***]
	  		  		  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
		  		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  			
	 [***]: [***]
	  		  		  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
		  		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  			
	 [***]: [***]
	  		  		  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
		  		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  			
	 [***]: [***]
	  		  		  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
		  		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  			
	 [***]
	  		  		  				  				  				  			
	 [***]
	  		  		  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  		  		  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  		  		  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
		  		  		  				  				  				  	 	[***]	  
	 [***]
	  		  		  				  				  				  			
	 [***]
	  		  		  				  				  				  			
	 [***]
	  	[***]	  	[***]	  				  				  				  	 	[***]	  
	 [***]
	  	[***]	  	[***]	  				  				  				  	 	[***]	  
	 [***]
	  	[***]	  	[***]	  				  				  				  	 	[***]	  
	 [***]
	  	[***]	  	[***]	  				  				  				  	 	[***]	  
	 [***]
	  	[***]	  	[***]	  				  				  				  	 	[***]	  
	 [***]
	  	[***]	  	[***]	  				  				  				  	 	[***]	  
	 [***]
	  	[***]	  	[***]	  				  				  				  	 	[***]	  
	 [***]
	  		  		  				  				  				  	 	[***]	  
	 [***]
	  		  		  				  				  				  			
	 [***]
	  		  		  				  				  				  	 	[***]	  
		  		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 [***]
	  		  		  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
		  		  		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 Total [***]
	  		  		  				  				  				  	 	[***]	  
		  		  		  				  				  				  	  
	  
	 

 * [***]. 
 Notes: 

 

	1	[***]. 

  

	2	[***]. 

  

	3	[***]. 

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

	4	[***]. 

  

	5	[***]. 

  

	6	[***]. 

  

	7	[***]. 

  

	8	[***]. 

  

	9	[***]. 

  

	10	[***]. 

  

	11	[***]. 

 ASSUMPTIONS: 
  

	1	[***] 

  

	2	[***]. 

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

 [***] Estimated Budget  

CONFIDENTIAL  
 [***]: [***] 

 

															
	 [***]
	  	 	[***]	  	  		  		  		  		  	
		  	  
	  
	 	  		  		  		  		  	
	 [***]
	  	 	[***]	  	  		  		  		  		  	
		  	  
	  
	 	  		  		  		  		  	
	 [***]: [***]
 Date, Version: [***]

Client & Protocol: Medpace – CHS-0214-02
[***]: [***]
[***]: [***]
[***]: [***]
[***]:
[***]
	  	Unit
Price
[***]	 	  	[***]	  	[***]	  	[***]	  	[***]	  	Total [***]
	 [***]
	  				  		  		  		  		  	
	 [***]
	  	 	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  				  		  		  		  		  	[***]
	 [***]
	  				  		  		  		  		  	
	 [***]
	  	 	[***]	  	  		  		  		  		  	[***]
	 [***]
	  	 	[***]	  	  		  		  		  		  	[***]
	 [***]
	  				  		  		  		  		  	[***]
	 [***]
	  				  		  		  		  		  	
	 [***]
	  	 	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	 	[***]	  	  		  		  		  	[***]	  	[***]
	 [***]
	  				  		  		  		  		  	[***]
		  				  		  		  		  		  	  

	 Total [***] 
	  				  		  		  		  		  	[***]
		  				  		  		  		  		  	  

 [***] Notes: 
  

	1	[***] 

 Additional [***] Clinical Trials Services 

 

													
	 [***]
	  		 	[***]	 		  		  		  	
	 [***]
	  	[***]	 		 		  		  		  	
		  	  
	 		 		  		  		  	
	 [***]
	  	[***]	 		 		  		  		  	
		  	  
	 		 		  		  		  	
	 [***]
	  	[***]	 		 		  		  		  	
		  	  
	 		 		  		  		  	
							
	 [***]
	  	 Unit Price

[***]
	 	[***]	 	[***]	  	[***]	  	[***]	  	Total
[***]
	 [***]
	  		 		 		  		  		  	
	 [***]
	  	[***]	 	[***]	 	[***]	  	[***]	  		  	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	  	[***]	  		  	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	  	[***]	  		  	[***]
	 [***]
	  		 		 		  		  		  	
	 [***]
	  	[***]	 	[***]	 	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	  	[***]	  		  	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	  	[***]	  		  	[***]
	 [***]
	  		 		 		  		  		  	
	 [***]
	  	[***]	 	[***]	 	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	  	[***]	  		  	[***]
	 [***]
	  	[***]	 	[***]	 	[***]	  	[***]	  		  	[***]

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

													
	 Total [***]
	  		  		  		  		  		  	[***]

 [***] Notes: 
 [***]
Estimated Budget  
 CONFIDENTIAL 

[***]: [***] 
  

																	
	 [***]
	  	 	[***]	  	  		  		  		  		  		  	
		  	  
	  
	 	  		  		  		  		  		  	
	 [***]
	  	 	[***]	  	  		  		  		  		  		  	
		  	  
	  
	 	  		  		  		  		  		  	
	 [***]
 Date, Version: [***]

Client & Protocol: Medpace – CHS-0214-02
[***]: [***]
[***]: [***]
[***]: [***]
[***]:
[***]
	  	Unit Price
[***]	 	  	Unit Price
[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	Total [***]
	 [***]
	  				  		  		  		  		  		  	
	 [***]
	  	 	[***]	  	  	[***]	  		  		  		  	[***]	  	[***]
	 [***]
	  				  		  		  		  		  		  	
	 [***]
	  	 	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  				  		  		  		  		  		  	[***]
	 [***]
	  				  		  		  		  		  		  	
	 [***]
	  				  		  		  		  		  		  	[***]
	 [***]
	  				  		  		  		  		  		  	
	 [***]
	  	 	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  				  		  		  		  		  		  	[***]
		  				  		  		  		  		  		  	  

	 Total [***]
	  				  		  		  		  		  		  	[***]
		  				  		  		  		  		  		  	  

 [***] Notes: 
  

	1	[***] 

 Additional [***] Clinical Trials Services 

 

																			
	 [***]
	  				  	 	[***]	  	  		  		  		  		  	
	 [***]
	  	 	[***]	  	  				  		  		  		  		  	
	 [***]
	  	 	[***]	  	  				  		  		  		  		  	
	 [***]
	  	 	[***]	  	  				  		  		  		  		  	
								
	 [***]
	  	Unit Price
[***]	 	  	Unit Price
[***]	 	  	[***]	  	[***]	  	[***]	  	[***]	  	Total [***]
	 [***]
	  				  				  		  		  		  		  	
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]	  	[***]	  		  	[***]
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]	  	[***]	  		  	[***]
	 [***]
	  				  				  		  		  		  		  	
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]	  	[***]	  		  	[***]
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]	  	[***]	  		  	[***]
	 [***]
	  				  				  		  		  		  		  	
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	[***]	  		  	[***]	  		  	[***]

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

																													
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
		  				  				  				  				  				  				  	  
	  
	 
	 Total [***]
	  				  				  				  				  				  				  	 	[***]	  
		  				  				  				  				  				  				  	  
	  
	 

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

 [***] Estimated Budget  

CONFIDENTIAL 
 [***]: [***] 

 

																													
	 [***]
	  	 	[***]	  	  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  				  				  				  				  				  			
	 [***]
 Date, Version: [***]

Client & Protocol: Medpace – CHS-0214-02
 [***]: [***]

[***]: [***]
 [***]: [***]

[***]: [***]
	  	Unit Price
[***]	 	  	Unit Price
[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	Total [***]	 
	 [***]
	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  			
	 [***]
	  				  				  				  				  				  				  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  			
	 [***]
	  				  				  				  				  				  				  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  	 	[***]	  
		  				  				  				  				  				  				  	  
	  
	 
	 Total [***]
	  				  				  				  				  				  				  	 	[***]	  
		  				  				  				  				  				  				  	  
	  
	 

 [***] Notes: 
  

	1	[***] 

 Additional [***] Clinical Trials Services 

 

																																	
	 [***]
	  				  	 	[***]	  	  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  				  				  				  				  				  				  			
	 [***]
	  	[***]	 	  	Unit Price	 	  	Unit Price
[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	[***]	 	  	Total
[***]	 
	 [***]
	  				  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  				  	 	[***]	  
	 [***]
	  				  				  				  				  				  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
		  				  				  				  				  				  				  				  	  
	  
	 
	 Total [***]
	  				  				  				  				  				  				  				  	 	[***]	  
		  				  				  				  				  				  				  				  	  
	  
	 

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

 CONFIDENTIAL  

[***] 
  

													
				
	 I [***]
	  				  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
				
	 II [***]
	  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
				
	 III [***]
	  				  				  			
	 [***]
	  				  				  			
	 [***]
	  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  				  				  			

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	

													
	 [***]
	  	 	[***]	  	  				  			
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  
	 [***]
	  	 	[***]	  	  	 	[***]	  	  	 	[***]	  

  

			
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.Prepared by R.R. Donnelley Financial -- EX-10.16(c)

 Exhibit 10.16(c) 

 

CONFIDENTIAL 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential
treatment has been requested with respect to the omitted portions. 

 AMENDMENT #2 TO TASK ORDER #13 

COHERUS Project Number: CHS0214-02 

MEDPACE Project Number: ETA302 

This Amendment #2 (“Amendment #2”) to Task Order #13 effective as of 18 October 2013 (“Task
Order”), is by and between Coherus Bioscience, Inc., a Delaware corporation with its principal place of business at 201 Redwood Shores Parkway, Suite 200, Redwood City, CA 94065 (“Sponsor”), and Medpace, Inc.,
with its principal place of business at 5375 Medpace Way, Cincinnati, Ohio 45227 (“Medpace”). This Amendment #2 shall be effective 21 May 2014. 

WITNESSETH: 

WHEREAS, the Parties have entered into Task Order pursuant and subject to the terms of the Master Service Agreement dated
23 January 2012, (the “Agreement”); and 
 WHEREAS, the Parties desire to amend Task Order in connection with a
Phase 3, A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 DP Versus Enbrel® in Subjects with Rheumatoid Arthritis and
Inadequate Response to Treatment with Methotrexate to include a portion of the Investigator payments for sites in Japan. 
 NOW,
THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows to the revised Scope of Work: 
  

	 	1.	The [***] Fees line item included under the Pre-Funded Expenses category in Appendix C: Services and Budget is hereby increased from [***] to [***]. (“Increase”). 

 

	 	2.	As a result of the increase in the Budget, Appendix D: Payment Schedule, attached to the Task Order is hereby amended to include the following: 

A total of [***] is due upon execution of Amendment #2. The remainder of the Increase will be paid in accordance with the terms of
Appendix D: Payment Schedule, attached to the Task Order. 
 The total amount payable by Sponsor to Medpace under this Amendment #2 for Medpace
Direct Fees, Pass-through Expenses, and Pre-funded Expenses shall not exceed the amount of [***] without prior written consent of both parties. The total value of Task Order and all subsequent amendments is now [***]. 

  

			
	

	  	 Amendment #2 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 1

																	
	 	  	Direct Fees	 	 	Pass Through Costs	 	 	Pre-funded Expenses	 	 	TOTAL	 
	 Task Order #13
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 Amendment #1
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 Amendment #2
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
	 TOTAL
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

 All other provisions of the Agreement and Task Order shall remain unchanged and in effect. 

IN WITNESS WHEREOF, the Parties have hereunto signed this Amendment #2 to Task Order in their official capacities which shall be effective on the
day and year listed above. 
  

			
	MEDPACE, INC.
		
	Signature:	 	/s/ John Wynne
		
	By:	 	John Wynne
		 	     (Print Name)
  

Vice President

	Title:	 	Commercial Operations

  

			
	COHERUS BIOSCIENCES, INC.
		
	Signature:	 	/s/ Dennis M. Lanfear
		
	By:	 	Dennis M. Lanfear
		 	    (Print Name)
		
	Title:	 	President & CEO

  

			
	

	  	 Amendment #2 to Task Order #13

Coherus Biosciences, Inc.
 CHS-0214-02
/ ETA302
 Page 2

			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00235-of-00352.parquet"}]]